Specific impairment of endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from streptozotocin-induced diabetic mice. 2006

Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan.

We hypothesized that the contribution made by endothelium-derived hyperpolarizing factor (EDHF) to acetylcholine (ACh)-induced endothelium-dependent relaxation (EDR) might be altered in mesenteric arteries from streptozotocin (STZ)-induced diabetic mice. In endothelium-intact preparations, the ACh-induced EDR (but not the sodium nitroprusside-induced relaxation) was weaker in the STZ group than in age-matched controls. Indomethacin (10 muM) had no significant effect on EDR in either group, indicating that cyclooxygenase products, including prostacyclin, are not involved. This indomethacin-resistant EDR was weaker in the STZ group than in the controls. To isolate the EDHF-resistant component of EDR, charybdotoxin (100 nM) and apamin (100 nM) were present in the bath solution throughout the next experiment. This EDHF-resistant relaxation did not differ significantly between the two groups. On the other hand, the EDHF-mediated relaxation was significantly weaker in the STZ group than in the controls, and it was completely blocked by lysophosphatidylcholine (LPC, 10 microM) in each group. The eNOS protein expression was similar between the two groups. These results suggest that (a) the endothelial dysfunction present in mesenteric arteries from type 1 diabetic mice is largely attributable to reduced EDHF signaling, and (b) LPC may be involved in this attenuation of EDHF-mediated relaxation.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008244 Lysophosphatidylcholines Derivatives of PHOSPHATIDYLCHOLINES obtained by their partial hydrolysis which removes one of the fatty acid moieties. Lysolecithin,Lysolecithins,Lysophosphatidylcholine
D008297 Male Males
D008638 Mesenteric Arteries Arteries which arise from the abdominal aorta and distribute to most of the intestines. Arteries, Mesenteric,Artery, Mesenteric,Mesenteric Artery
D009599 Nitroprusside A powerful vasodilator used in emergencies to lower blood pressure or to improve cardiac function. It is also an indicator for free sulfhydryl groups in proteins. Nitroferricyanide,Sodium Nitroprusside,Cyanonitrosylferrate,Ketostix,Naniprus,Nipride,Nipruton,Nitriate,Nitropress,Nitroprussiat Fides,Nitroprusside, Disodium Salt,Nitroprusside, Disodium Salt, Dihydrate,Disodium Salt Nitroprusside,Nitroprusside, Sodium
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000097003 Gap Junction alpha-5 Protein A GAP JUNCTION alpha subunit containing four transmembrane domains expressed in the atrial myocardium and ventricular HEART CONDUCTION SYSTEM including PURKINJE FIBERS. Mutations in the human gene GJA5 are associated with cardiac conduction abnormalities such as a familial ATRIAL FIBRILLATION. Connexin 40,Connexin 40 Protein,GJA5 Protein,Gap Junction A5,Gap Junction alpha5 Protein,Gap Junction alpha 5 Protein,Protein, Connexin 40,Protein, GJA5

Related Publications

Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
November 2005, American journal of physiology. Heart and circulatory physiology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
December 2006, European journal of pharmacology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
August 1997, British journal of pharmacology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
December 2008, European journal of pharmacology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
October 1998, British journal of pharmacology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
January 1995, General pharmacology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
October 1992, British journal of pharmacology,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
January 2012, Circulation research,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
January 2002, Biochemical and biophysical research communications,
Takayuki Matsumoto, and Kiyoto Miyamori, and Tsuneo Kobayashi, and Katsuo Kamata
November 2013, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!